Acadian Asset Management
APTO

Acadian Asset Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Acadian Asset Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-19
Closed -$27K – 1892
2018
Q1 		$27K Sell
19
-80
-81% -$107K ﹤0.01% 1458
2017
Q4 		$100K Buy
99
+75
+313% +$58K ﹤0.01% 1096
2017
Q3 		$16K Buy
+24
New +$16.1K ﹤0.01% 1246

Other funds holding APTO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Acadian Asset Management's APTO Position: Q2 2018 in Review

Acadian Asset Management sold out of Aptose Biosciences, Inc. (APTO) in Q2 2018, closing a stake of 19 shares — an estimated $27K sold.

Acadian Asset Management first reported a position in APTO in Q3 2017 and held it in 3 quarters. The position peaked at $100K in Q4 2017. 21 funds tracked by Wall St. Rank hold APTO as of Q2 2018.

  • Acadian Asset Management reported no remaining Aptose Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
  • Acadian Asset Management sold 19 Aptose Biosciences, Inc. shares in Q2 2018, an estimated $27K.
  • Acadian Asset Management first reported a position in Aptose Biosciences, Inc. in Q3 2017 and held it in 3 quarters.
  • Acadian Asset Management's Aptose Biosciences, Inc. position peaked at $100K in Q4 2017.
  • 21 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2018.

Based on Acadian Asset Management's 13F filing for Q2 2018, filed 24 Jul 2018.